[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-gastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-gastric-cancer":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,57,87,109,134,158,188,209,240,267,290,312,344,365,386,406,428,448,475,501],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":41,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100633678","phase-1-phase-12-study-of-bhb810-in-advanced-gastric-and-gej-adenocarcinoma-100633678",false,"NCT07529808","Phase 1\u002F2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","Phase 1\u002F2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.\n* Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.\n\n  * Participants in Phase 1 Backfill Cohorts \\& Phase 2 must be CDH17-positive by central testing.\n  * Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.\n* At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\n* Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.\n* Adequate organ and marrow function as defined in the protocol\n\nExclusion Criteria:\n\n* Prior cancer treatment as follows, relative to the first planned dose of trial intervention:\n\n  * Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)\n  * Monoclonal antibody-based therapy (including ADCs) within 4 weeks\n  * Immune checkpoint inhibitors within 4 weeks\n  * Wide-field radiation therapy (\\>30% marrow-bearing bones) within 4 weeks or \\\u003C 2 weeks of focal palliative radiation to nontarget lesions\n* Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)\n* Known hypersensitivity or allergic reaction to BHB810 or it's excipients\n* Left ventricular ejection fraction \\\u003C50% or history of congestive heart failure Class III\u002FIV\n* QTc interval \\> 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT\u002FQTc\n* Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant\n* Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.\n* Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention\n* Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.","ALL","18 Years",{"count":19,"type":20},164,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Gastric Cancer","Gastric Adenocarcinoma","Gastric (Stomach) Cancer","Gastroesophageal Adenocarcinoma","Gastroesophageal Cancer (GC)","Gastroesophageal Junction (GEJ) Adenocarcinoma","Gastroesophageal Junction (GEJ) Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Adenocarcinoma","Gastrointestinal Cancers","Colorectal (Colon or Rectal) Cancer","Pancreatic Cancer","CDH17-positive Advanced Solid Tumors","Advanced Gastric Cancer",[42,43,44],"Antibody Drug Conjugate (ADC)","Monomethyl Auristatin E (MMAE)","CDH17 protein","NOT_YET_RECRUITING","2026-05-05",{"date":48,"type":49},"2026-05-08","ACTUAL",{"date":51,"type":20},"2026-06",{"date":53,"type":20},"2028-12",{"name":55,"class":56},"BigHat Biosciences, Inc.","INDUSTRY",{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100634258","phase-2-safety-and-efficacy-of-leucine-restricted-diet-combined-with-chemotherapy-and-immunotherapy-in-advanced-gastric-cancer-100634258","NCT07537348","Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer","A Study on the Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer Patients Treated With Chemotherapy and Immunotherapy","LUCENT-GC-03","Inclusion Criteria:\n\n* Diagnosis and Treatment Plan: Patients with advanced gastric cancer with distant metastasis, confirmed by imaging modalities (such as CT or PET-CT) and clinical pathological data, who are indicated for combined chemotherapy and immunotherapy.\n* Demographics: Aged 18 to 70 years, regardless of gender.\n* Dietary Capability: Capable of oral intake or receiving liquid diet via nasogastric tube.\n* Consent: Willing to participate in this study and have signed the Informed Consent Form (ICF).\n* Exclusion of Other Malignancies: No concurrent primary malignant tumors other than gastric cancer.\n\nExclusion Criteria:\n\n* Cognitive or Psychiatric Impairment: Cognitive dysfunction or psychiatric disorders that prevent the patient from understanding the study content or providing informed consent.\n* Diabetes Mellitus: Diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Gastrointestinal Conditions: Presence of severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralytic or mechanical intestinal obstruction, or active gastrointestinal bleeding.\n* Allergy：Known hypersensitivity or allergy to any of the main components of the leucine-deficient nutritional powder.\n* Concomitant Supplements: Current use of other nutritional supplements that may potentially confound the study results or affect efficacy evaluation.\n* Treatment Tolerance: Inability to tolerate combined chemotherapy and immunotherapy, or occurrence of severe gastrointestinal adverse events following such treatment.","70 Years",{"count":67,"type":20},73,[24],"Based on existing literature, we posit that a leucine-restricted diet is safe and well-tolerated in patients with advanced gastric cancer receiving combined chemotherapy and immunotherapy. Patients adhering to this dietary regimen exhibit a significant reduction in serum leucine concentrations, with no notable impact on the serum levels of other amino acids. Furthermore, leucine restriction promotes the activation of immune cells within the tumor microenvironment. When applied in conjunction with chemotherapy and immunotherapy for advanced gastric cancer, this approach demonstrates synergistic anti-tumor efficacy. It is expected to enhance tumor response rates , improve the 1-year survival rate, prolong overall survival (OS), and ultimately optimize patient prognosis.",[40],[40,72,73,74],"Leucine-Restricted Diet","Chemotherapy","Immunotherapy","RECRUITING","2026-04-15",{"date":78,"type":49},"2026-04-17",{"date":80,"type":49},"2026-01-01",{"date":82,"type":20},"2028-12-31",{"name":84,"class":85},"Qilu Hospital of Shandong University","OTHER",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":86},"100615596","phase-2-pd1tgf-in-combination-with-shr2554-or-apatinib-and-chemotherapy-for-first---line-treatment-of-gastric-cancer-100615596","NCT07294664","PD1\u002FTGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer","Clinical Study of SHR1701 in Combination With CAPOX and SHR2554 or Apatinib for First-line Treatment of Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Patients voluntarily agree to participate in this study and sign the informed consent form;\n2. Age ≥ 18 years;\n3. ECOG PS score 0-2;\n4. Pathologically confirmed adenocarcinoma of the stomach\u002Fgastroesophageal junction;\n5. Clinical staging based on contrast - enhanced CT\u002FMRI (with endoscopic ultrasound and diagnostic laparoscopy if necessary). Patients with stage III-IV (8th edition of the AJCC Gastric Cancer TNM Staging) non - resectable locally advanced or metastatic disease; the feasibility of curative surgery for patients is determined by multidisciplinary team (MDT) discussion;\n6. Patients who have not previously received systemic therapy for advanced disease;Note: Neoadjuvant therapy is not counted as a line of therapy. If recurrence occurs within 6 months after completion of adjuvant therapy, the adjuvant therapy is defined as first - line therapy. If recurrence occurs more than 6 months after completion of adjuvant therapy, the adjuvant therapy is not counted as a line of therapy.\n7. Have measurable lesions meeting Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;\n8. Subjects' baseline blood routine and biochemical indices meet the following criteria (no blood transfusion\u002Fblood products received, and no granulocyte colony - stimulating factor (G - CSF) or other hematopoietic growth factors used for correction within 14 days before the first dose):\n\n   Hemoglobin ≥ 90 g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL; Platelets ≥ 80×10\\^9\u002FL; ALT, AST ≤ 2.5 × upper limit of normal (ULN); if the patient has liver metastasis, ALT and AST ≤ 5 × ULN; Serum total bilirubin ≤ 1.5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN or estimated creatinine clearance \\> 50 mL\u002Fmin (For males: Creatinine clearance = ((140 - age) × weight) \u002F (72 × serum Cr); For females: Creatinine clearance = ((140 - age) × weight) \u002F (72 × serum Cr) × 0.85; Weight unit: kg; Serum Cr unit: mg\u002FmL); Serum albumin ≥ 30 g\u002FL;\n9. No serious concurrent diseases that would result in a life expectancy of \\\u003C 5 years\n10. Female subjects of childbearing potential must undergo a serum pregnancy test within 72 hours prior to the first dose, with a negative result, and agree to use highly effective methods of contraception during treatment and for 90 days after the end of treatment. For male subjects whose partners are female of childbearing potential, they must agree to use highly effective methods of contraception during treatment and for 90 days after the end of treatment.\n11. Agree to provide blood and\u002For histological specimens.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Known HER2 positivity;\n3. Patients with adverse events from previous treatments (except alopecia) that have not resolved to ≤ Grade 1 (CTCAE v5.0);\n4. History of other malignant diseases within the past 5 years or concurrent malignant diseases, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix;\n5. History of uncontrolled epilepsy, central nervous system diseases, or mental disorders, where the investigator judges that the clinical severity may hinder the signing of informed consent or affect the patient's adherence to oral medications;\n6. Clinically significant (i.e., active) heart disease that is not well-controlled, such as: (1) Symptomatic coronary heart disease; (2) New York Heart Association (NYHA) Class II or worse congestive heart failure or severe arrhythmias requiring medication intervention; (3) Myocardial infarction within the past 12 months; (4) QTc interval ≥ 450 ms in males or ≥ 470 ms in females; (5) Left ventricular ejection fraction (LVEF) \\\u003C 50%;\n7. Arterial\u002Fvenous thrombotic events within 6 months, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary embolism, etc.;\n8. Clinically significant bleeding symptoms or definite bleeding tendency within 3 months, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, etc. If fecal occult blood is positive during screening, a re-examination is allowed; if still positive after re-examination, gastroscopy may be performed as clinically indicated (except those who have undergone gastroscopy within 3 months before enrollment to rule out such conditions);\n9. Known hereditary or acquired bleeding and thrombotic tendencies (e.g., patients with hemophilia, coagulopathy, thrombocytopenia, etc.);\n10. Patients with upper gastrointestinal obstruction, abnormal physiological function, or malabsorption syndrome that may affect the absorption of oral medications; patients with a history of gastrointestinal perforation, intra-abdominal abscess, or intestinal obstruction within the past 3 months, or with imaging findings\u002Fclinical symptoms suggesting concurrent intestinal obstruction;\n11. Abnormal coagulation function (INR \\> 2.0 or prothrombin time \\> 16 seconds), with bleeding tendency or receiving thrombolytic or anticoagulant therapy (prophylactic use of low-dose aspirin, low-molecular-weight heparin, etc., is allowed);\n12. Patients with chemotherapy-induced neurotoxicity who are judged by the investigator as unsuitable for oxaliplatin use cannot be included in Intervention Arm 1; however, patients with only deep tendon reflex (DTR) loss may not be excluded;\n13. Patients who have undergone organ transplantation and require immunosuppressive therapy; patients who have used immunosuppressive drugs or systemic corticosteroids for immunosuppressive purposes within 14 days prior to the first dose (e.g., \\> 10 mg\u002Fday prednisone or equivalent dose of other drugs);\n14. With active ulcers, unhealed wounds, or fractures;\n15. Patients with hypertension that cannot be well-controlled with antihypertensive medications (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg);\n16. Known hypersensitivity to any investigational drugs or excipients; Urinalysis indicating urinary protein ≥ ++, with confirmed 24-hour urinary protein excretion \\> 1.0 g;\n17. Patients with clinically symptomatic serous cavity effusions (including ascites, pleural effusion, pericardial effusion) requiring symptomatic management; asymptomatic serous cavity effusion patients are allowed to enroll; patients with symptomatic serous cavity effusions that are well-controlled after active management such as drainage may be enrolled at the investigator's discretion;\n18. Active hepatitis (for hepatitis B: HBsAg positive with HBV DNA ≥ 500 IU\u002Fml; for hepatitis C: HCV antibody positive with HCV viral load \\> upper limit of normal); patients in active infection phase requiring antimicrobial therapy (e.g., antibacterial or antifungal treatment);\n19. Currently having interstitial pneumonia or interstitial lung disease, or other conditions that may interfere with the judgment and management of immune-related pulmonary toxicity, such as pulmonary fibrosis, organizing pneumonia, pneumoconiosis, drug-related pneumonia, idiopathic pneumonia, or those with active pneumonia or severe pulmonary function impairment shown by screening CT; patients with active pulmonary tuberculosis;\n20. Patients with active autoimmune diseases or a history of autoimmune diseases with potential for recurrence (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism \\[subjects whose condition is controllable with hormone replacement therapy may be included\\]); patients with skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, alopecia), type 1 diabetes mellitus controllable with insulin therapy, or those with a history of childhood asthma that has completely resolved without any intervention may be enrolled; asthmatic patients requiring bronchodilators for intervention cannot be enrolled.",{"count":95,"type":20},78,[24],"Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach. This study aims to evaluate the addition of immunomodulatory EZH2 inhibitors or anti-angiogenic agents to the baseline regimen of immunotherapy combined with chemotherapy, in order to further improve patient treatment benefits.",[40,99],"SHR1701","2026-04-13",{"date":102,"type":49},"2026-04-16",{"date":104,"type":49},"2025-06-15",{"date":106,"type":20},"2028-07-15",{"name":108,"class":85},"The First Affiliated Hospital of Zhengzhou University",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":86},"100630333","phase-2-evaluation-of-pressurized-intraperitoneal-aerosol-chemotherapy-with-vrt106-versus-pipac-in-patients-with-advanced-gastric-cancer-and-peritonealmetastasis-a-prospective-multicenter-open-label-randomized-controlled-trial-100630333","NCT07486310","Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 75 years, inclusive, regardless of gender.\n2. Histologically or pathologically confirmed gastric adenocarcinoma with peritoneal metastasis (confirmed by imaging findings, previous surgical pathology, or positive cytology from ascites\u002Fperitoneal fluid), and assessed by the investigator as having unresectable peritoneal lesions with a PCI score \\> 6.\n3. Subjects with no contraindications for laparoscopic surgery.\n4. ECOG performance status ≤ 1.\n5. Expected survival time ≥ 6 months.\n6. No blood transfusion or treatment with hematopoietic stimulating factors within 14 days before screening, and meeting the following criteria:\n\n   * Hematology: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL, platelet count (PLT) ≥ 100 × 10⁹\u002FL, hemoglobin (Hb) ≥ 90 g\u002FL.\n   * Blood biochemistry: Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN) (≤ 3.0 × ULN for subjects with Gilbert syndrome); alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) ≤ 3.0 × ULN; albumin ≥ 2.8 g\u002FdL; creatinine ≤ 1.5 × ULN; or creatinine clearance (Ccr) ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula, only required if creatinine \\> 1.5 × ULN).\n   * Coagulation function: Activated partial thromboplastin time (APTT), international normalized ratio (INR), or prothrombin time (PT) ≤ 1.5 × ULN.\n7. Female subjects of childbearing potential or male subjects with partners of childbearing potential must use effective contraception throughout the treatment period and for 3 months after the last dose.\n8. Voluntary participation in the clinical study, with full understanding and signed informed consent form (ICF); willingness and ability to comply with all trial procedures.\n\nExclusion Criteria:\n\n* 1\\. Subjects with gastrointestinal obstruction; 2. Subjects completely dependent on parenteral nutrition; 3. Subjects with decompensated ascites; 4. Subjects with severe abdominal infection (manifesting as peritonitis); 5. Subjects with extensive abdominal adhesions; 6. Subjects undergoing simultaneous cytoreductive surgery and gastrointestinal resection and reconstruction; 7. Subjects with concurrent portal vein thrombosis; 8. Known allergy to any component of the VRT106 formulation (mannitol, human albumin, trehalose, etc.) or to chemotherapy drugs; 9. Use of live attenuated vaccines within 4 weeks prior to the first dose of the study drug, including but not limited to: measles, mumps, rubella, varicella\u002Fzoster, yellow fever, rabies, BCG, and typhoid vaccines. Seasonal influenza vaccines for injection are inactivated virus vaccines and are allowed; intranasal influenza vaccines are live attenuated and are not allowed; 10. Use of systemic glucocorticoids (prednisone \\> 10 mg\u002Fday or equivalent dose of similar drugs) or other immunosuppressive therapy within 1 week prior to the first dose of the study drug, except for the following:\n* Use of topical, ocular, intra-articular, intranasal, and inhaled corticosteroids;\n* Use of corticosteroids for prophylactic treatment (e.g., prevention of contrast agent allergy); 11. Use of immunomodulatory drugs, including but not limited to thymosin, interleukin-2, interferon, etc., within 14 days prior to the first dose of the study drug; 12. Subjects with active autoimmune disease or a history of autoimmune disease that may recur. However, subjects with the following diseases are not excluded and may be further screened: a. Type 1 diabetes; b. Hypothyroidism (if controlled by hormone replacement therapy alone); c. Controlled celiac disease; d. Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia); e. Any other disease not expected to recur in the absence of an external trigger; 13. History of splenectomy; 14. Adverse reactions from prior anti-tumor therapy have not recovered to ≤ Grade 1 per NCI-CTCAE v5.0 (excluding alopecia, chemotherapy-induced Grade 2 neurotoxicity, and other toxicities deemed by the investigator to pose no safety risk); 15. History of severe cardiovascular disease, including but not limited to:\n* Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, second- or third-degree atrioventricular block, QT interval corrected using Fridericia's formula (QTcF) ≥ 480 ms, etc.;\n* Occurrence of acute coronary syndrome, acute myocardial infarction, congestive heart failure, stroke, or other Grade 3 or higher cardiovascular events within 6 months prior to the first dose of the study drug;\n* New York Heart Association (NYHA) functional class ≥ II, or left ventricular ejection fraction (LVEF) \\\u003C 50%;\n* Poorly controlled hypertension per investigator judgment (hypertension not controlled despite standard treatment: systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg); 16. Uncontrolled active infection requiring systemic therapy; 17. Presence of other invasive malignancies besides the study disease. Exceptions include: cured basal cell or squamous cell carcinoma of the skin, carcinoma in situ (e.g., breast cancer, cervical carcinoma in situ), superficial bladder cancer, or malignancies with no recurrence and no treatment for the past 2 years; 18. Pregnant or breastfeeding women; 19. Subjects deemed by the investigator to have other serious systemic diseases or other reasons making them unsuitable for participation in this clinical trial; 20. Subjects who have received other unmarketed investigational drugs\u002Fdevice therapies within 4 weeks prior to the first dose of the study drug; 21. Concurrent enrollment in another clinical study, except for observational (non-interventional) clinical studies or the follow-up phase of an interventional study (must be judged by the investigator as not impacting the efficacy and safety evaluation of this study).","75 Years",{"count":117,"type":20},30,[24],"This study is a prospective, multicenter, open-label, randomized controlled clinical trial, planned to enroll 30 patients with advanced gastric cancer and peritoneal metastasis. It aims to evaluate the safety and efficacy of systemic therapy plus Pressurized Intra-Peritoneal Aerosol Virus (PIPAV) with VRT106 compared to systemic therapy plus Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC).",[40],[122,123,124],"Pressurized Intra-Peritoneal Aerosol","VRT106","advanced gastric cancer with peritoneal metastasis","2026-03-17",{"date":127,"type":49},"2026-03-20",{"date":129,"type":20},"2026-03-01",{"date":131,"type":20},"2029-06-01",{"name":133,"class":85},"Guangdong Provincial People's Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":65,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":86},"100615868","phase-1-clinical-trial-on-the-safety-tolerance-and-preliminary-efficacy-of-xh001-injection-combined-with-neoantigen-vaccine-induced-tumor-specific-t-cell-injection-in-advanced-gastric-cancer-100615868","NCT07298200","Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer","A Single-center, Non-randomized, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer.","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Aged between 18 and 70 years old, male or female.\n3. Advanced gastric cancer that has been diagnosed by histological and\u002For cellular pathology, and which has failed to respond to second-line standard treatment or is intolerant to it, or is not suitable for standard treatment at this stage.\n4. According to the RECIST 1.1 criteria for evaluating the efficacy of solid tumors, there must be at least one measurable lesion as the target lesion for efficacy evaluation. The total diameter of the overall tumor lesion (excluding bone metastases) should be ≤ 100mm, and the diameter of a single tumor lesion should be ≤ 30mm. If the lesion that has received local treatment (radiotherapy, ablation, vascular intervention, etc.) is the only lesion, then there must be clear imaging evidence of disease progression for this lesion.\n5. Expected survival duration ≥ 12 weeks.\n6. Adequate organ and bone marrow function.\n\nExclusion Criteria:\n\n1. Requires long-term systemic administration of antiallergic drugs, or has severe hypersensitivity reactions (≥Grade 3) to XH001 injection and\u002For any of its excipients.\n2. Central nervous system metastases with symptoms and without prior treatment, and\u002For meningeal metastases.\n3. Having received immunomodulatory drug therapy within 2 weeks prior to the first administration day (D1) of XH001 injection.\n4. Suffer from skin diseases that may prevent the intradermal injection from reaching the target area (such as psoriasis).\n5. Subjects with toxic side effects from previous treatment that have not recovered to CTCAE grade≤2, excluding hair loss.\n6. Subjects who received systemic steroid treatment (daily dose exceeding 10mg of prednisone equivalent) or any other form of immunosuppressive treatment within 7 days before the first administration of XH001 injection, excluding:1) Intranasal inhalation of local steroids or local steroid injection (such as intra-articular injection); 2) Systemic corticosteroid treatment not exceeding 10mg\u002Fday of prednisone or its equivalent physiological dose.\n7. Subjects who have previously received therapeutic tumor vaccines or therapeutic cell therapy products.\n8. Previously received allogeneic hematopoietic stem cell or allogeneic bone marrow transplantation, or previously received solid organ transplantation, or currently using immunosuppressive drugs.\n9. Have active or poorly controlled severe infections during screening period.\n10. Virological tests show positive for human immunodeficiency virus antibodies, hepatitis B surface antigen and\u002For hepatitis B core antibody with hepatitis B virus DNA \\> 1000 IU\u002Fml, positive for hepatitis C virus antibodies, and positive for Treponema pallidum specific antibodies.\n11. Patients with other malignancies within 5 years before enrollment, except for those with a history of appropriately treated and cured cervical carcinoma in situ, breast carcinoma in situ, or skin basal cell carcinoma.\n12. Any history of autoimmune diseases.\n13. Known to have active pulmonary tuberculosis (TB).\n14. Patients who have received systemic chemotherapy, radiotherapy, molecular targeted therapy, biological immunotherapy, hormone therapy or unapproved clinical trial drugs\u002Finstruments within 2 weeks before screening.\n15. Subjects who are still participating in other clinical trials during the screening period.\n16. Pregnant or lactating women.\n17. Other severe, acute, or chronic medical or psychiatric conditions, or laboratory abnormalities, that, to the investigator's discretion, may increase the risks of participating in the trial or may interfere with the interpretation of the trial results.",{"count":142,"type":20},18,[23],"The goal of this clinical trial is to learn the safety of tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell in treating advanced gastric cancer in adults. It will also learn if the combined treatment works to treat advanced gastric cancer.\n\nThe main questions it aims to answer are:\n\nWhat medical problems do participants have when using the combined treatment? Does tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell eliminate or shrink the tumor, and can it prolong the patient's survival period?",[40],[40,147,148],"Tumor neoantigen","Tumor neoantigen induced tumor-specific T -cell","2026-02-23",{"date":151,"type":49},"2026-02-25",{"date":153,"type":49},"2025-12-26",{"date":155,"type":20},"2029-11",{"name":157,"class":85},"Jia Wei",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":164,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100624153","evaluation-of-the-effectiveness-of-managing-chemotherapy-side-effects-using-epro-and-a-standardized-telenursing-program-for-cancer-patients-100624153","NCT07405931","Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Diagnosed with early or advanced gastric, lung, breast, or colon cancer\n* Starting first-cycle chemotherapy with a new anticancer agent\n* Able to use a smartphone without difficulty\n* Willing to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons\n* Individuals who cannot read, write, or understand Korean\n* Other individuals deemed inappropriate for participation by the investigators","19 Years",{"count":166,"type":20},414,[168],"NA","This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.",[171,40,172,173,174,175,176,177],"Early Gastric Cancer","Early Lung Cancer","Advanced Lung Cancer","Early Breast Cancer","Advanced Breast Cancer","Early Colon Cancer","Advanced Colon Cancer","2026-02-08",{"date":180,"type":49},"2026-02-12",{"date":182,"type":49},"2025-07-09",{"date":184,"type":20},"2026-09",{"name":186,"class":85},"Ulsan University Hospital",5,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":207,"locationsCount":4},"100621534","a-prospective-single-arm-exploratory-study-of-trifluridinetipiracil-tas-102-combined-with-apatinib-as-third-line-therapy-for-advanced-gastric-cancer-100621534","NCT07371871","A Prospective, Single-arm, Exploratory Study of Trifluridine\u002FTipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer","Inclusion Criteria:\n\n* Gastric cancer confirmed by histopathological or cytological diagnosis;\n* unresectable locally advanced or recurrent\u002Fmetastatic gastric cancer;\n* age 18-75 years, regardless of gender;\n* ECOG score 0-2;\n* previously received second-line treatment for advanced gastric cancer with disease progression during or after treatment;\n* at least one measurable lesion present according to RECIST 1.1 criteria;\n* laboratory tests meeting the following requirements: (1) Blood routine: HGB≥70g\u002FL; WBC≥4.0×10\\^9\u002FL; NEUT≥1.5×10\\^9\u002FL; PLT≥90×10\\^9\u002FL; (2) Blood biochemistry: ALT, AST≤2.5×upper limit of normal (ULN), serum creatinine≤1.5×upper limit of normal;\n* negative pregnancy test for patients of childbearing potential and voluntary use of effective and reliable contraception during the trial.\n\nExclusion Criteria:\n\n* Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment;\n* Any of the following conditions that may interfere with oral medication: inability to swallow, chronic diarrhea, or intestinal obstruction;\n* Concurrent receipt of any other systemic anti-tumor therapy (excluding local treatment);\n* Previous treatment with VEGFR inhibitors (excluding ramucirumab; pan-targeted TKIs are excluded);\n* Known history of allergy to any component of the study drugs;\n* Subjects with active infectious diseases;\n* Patients deemed unsuitable for enrollment by the investigator due to potential increased study-related risks or possible interference with interpretation of study results, as assessed by the investigator.",{"count":117,"type":20},[168],"To evaluate the efficacy and safety of trifluridine\u002Ftipiracil (TAS-102) combined with apatinib as third-line therapy for advanced gastric cancer",[40],[40,199,200],"TAS-102","Apatinib","2026-01-19",{"date":203,"type":49},"2026-01-28",{"date":205,"type":20},"2026-01-08",{"date":82,"type":20},{"name":208,"class":85},"Anhui Provincial Cancer Hospital",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":86},"100617225","phase-2-iparomlimab-and-tuvonralimab-ql1706-combined-with-chemotherapy-for-previously-untreated-advanced-or-metastatic-gastric-or-gastroesophageal-junction-cancer-100617225","NCT07315854","Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","A Prospective, Single-Center, Exploratory Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy in the Treatment of Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","Inclusion Criteria:\n\n* Voluntarily participate in the clinical study; fully understand and are informed about the study and sign the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures.\n* Age 18-80 years, gender is not limited.\n* Patients with locally advanced unresectable, recurrent unresectable, or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) confirmed by imaging and other examinations, and histopathologically confirmed as adenocarcinoma.\n* Provide a report confirming HER2 overexpression or amplification negativity; defined as IHC 0\u002F1+, or IHC 2+ with FISH\u002FISH negative.\n* No prior systemic therapy for advanced or metastatic GC\u002FGEJC (including anti-HER-2 therapy). Patients who have received adjuvant or neoadjuvant therapy (including chemotherapy, radiotherapy, or chemoradiotherapy) for GC\u002FGEJC are eligible if the time to first recurrence or disease progression is greater than 6 months from the end of the last treatment. Prior use of anti-tumor Traditional Chinese Medicine preparations is allowed but must be discontinued at least 2 weeks before enrollment.\n* ECOG performance status score of 0 or 1.\n* Must have at least one measurable lesion according to RECIST v1.1 definitions.\n* All acute toxicities caused by prior anti-tumor therapy or surgery must have resolved to Grade 0-1 (according to NCI CTCAE v5.0) or to the level specified in the inclusion\u002Fexclusion criteria. Alopecia, fatigue, and hearing loss, or other toxicities considered by the investigator not to pose a safety risk to the subject, are excluded.\n* Adequate organ function (laboratory tests within 7 days prior to treatment):\n\n  * Hematology (No blood transfusion, G-CSF use, or drug correction within 14 days prior to screening):\n  * White blood cell count (WBC) ≥ 3,000\u002Fmm³ (3.0 × 10⁹\u002FL);\n  * Absolute neutrophil count (ANC) ≥ 1,500\u002Fmm³ (1.5 × 10⁹\u002FL);\n  * Platelet count (PLT) ≥ 100,000\u002Fmm³ (100 × 10⁹\u002FL);\n  * Hemoglobin (Hb) ≥ 9.0 g\u002FdL (90 g\u002FL).\n* Biochemistry (No albumin transfusion within 14 days prior to screening):\n\n  * Albumin ≥ 3.0 g\u002FdL (30 g\u002FL);\n  * Creatinine ≤ 1.5 × Upper Limit of Normal (ULN) or Creatinine Clearance ≥ 50 ml\u002Fmin (calculated using the Cockcroft-Gault formula);\n  * Total Bilirubin (BIL) ≤ 1.5 × ULN;\n  * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels ≤ 2.5 × ULN; for patients with liver metastases, ≤ 5 × ULN.\n* Coagulation: International Normalized Ratio (INR) ≤ 1.5, Prothrombin Time (PT), and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.\n* Urine: Urine protein \\\u003C 2+; if urine protein is ≥ 2+, 24-hour urine protein quantification must be ≤ 1g.\n* Life expectancy ≥ 3 months.\n* Women of childbearing potential must undergo a serum or urine pregnancy test within 7 days before starting treatment, with a negative result, and must not be lactating. All enrolled patients must use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n* Known squamous cell carcinoma, undifferentiated carcinoma, other histological types of gastric cancer, or mixed gastric cancer containing other histological types.\n* Active malignant tumors within the past 2 years, other than the tumor under study. Exceptions include subjects with locally curable cancers (that have been cured), such as basal or squamous cell skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix or breast.\n* Participation in a study of an investigational drug or receipt of investigational treatment or use of an investigational device within 4 weeks prior to the first dose.\n* Enrollment in another clinical study, unless it is an observational, non-interventional clinical study or the follow-up period of an interventional study (defined as \\>4 weeks since the last dose of the previous clinical study or \\>5 half-lives of the study drug).\n* Untreated Central Nervous System (CNS) metastases, or uncontrolled or symptomatic active CNS metastases. Patients with fully treated CNS metastases may be enrolled if neurological symptoms have returned to baseline levels at least 4 weeks prior to enrollment (excluding residual signs or symptoms related to CNS treatment). Additionally, subjects must have discontinued corticosteroids or be on a stable or tapering dose of prednisone ≤ 10 mg\u002Fd (or equivalent dose of other corticosteroids) for at least 4 weeks prior to enrollment.\n* Pleural effusion or ascites that remains uncontrolled despite puncture and drainage within 14 days prior to enrollment; symptomatic or moderate-to-large pericardial effusion.\n* Weight loss of more than 20% within 2 months prior to enrollment.\n* Received the following treatments or medications prior to enrollment:\n\n  * Major surgery within 28 days prior to enrollment (tissue biopsy for diagnosis and PICC\u002Fport implantation are allowed).\n  * Use of immunosuppressive drugs within 14 days prior to enrollment, excluding nasal\u002Finhaled corticosteroids or physiological doses of systemic steroids (i.e., ≤ 10 mg\u002Fd prednisone or equivalent).\n  * Vaccination with live attenuated vaccines within 28 days prior to enrollment or planned during the study period and within 60 days after the end of study drug treatment.\n  * Local anti-tumor therapy (e.g., radiotherapy or tumor embolization) within 28 days prior to enrollment.\n* Diagnosed with any other malignant tumor within 5 years prior to entering the study, except for cured cutaneous basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma amenable to local treatment.\n* Presence of any active, known, or suspected autoimmune disease. Subjects in a stable state not requiring systemic immunosuppressive therapy are allowed, such as Type I diabetes, hypothyroidism requiring only hormone replacement therapy, and skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia).\n* Prior treatment with any anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.\n* Significant clinical bleeding symptoms or definite bleeding tendency within 3 months prior to enrollment; gastrointestinal perforation and\u002For fistula within 6 months prior to enrollment; arterial\u002Fvenous thromboembolic events within 6 months prior to enrollment, such as cerebrovascular accident (including TIA, cerebral infarction), deep vein thrombosis, and pulmonary embolism (except for those with gastric cancer bleeding\u002Fperforation where symptoms disappeared after surgical resection).\n* Major vascular disease within 6 months before the start of study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis).\n* Severe, unhealed, or dehisced wounds, active ulcers, or untreated fractures.\n* Presence of \\> Grade 1 peripheral neuropathy.\n* History of intestinal obstruction and\u002For clinical signs or symptoms of gastrointestinal obstruction within 6 months before starting study treatment, including incomplete obstruction related to the underlying disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding. Patients with incomplete obstruction\u002Fobstruction syndrome at initial diagnosis who have symptom relief after definitive (surgical) treatment may be enrolled.\n* Interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, acute pneumonia, etc.).\n* Known history of active tuberculosis.\n* Known allergy to the study drug or any of its excipients; or history of severe allergic reactions to other monoclonal antibodies.\n* HIV infection or known Acquired Immunodeficiency Syndrome (AIDS); untreated active hepatitis (Hepatitis B defined as HBV-DNA ≥ 500 IU\u002Fml; Hepatitis C defined as anti-HCV positive and HCV RNA above the lower limit of detection) or co-infection with Hepatitis B and C.\n* Poorly controlled clinical cardiac symptoms or diseases, such as: (1) NYHA Class II or higher cardiac insufficiency or LVEF \\\u003C 50% on echocardiography; (2) Severe\u002Funstable angina; (3) Myocardial infarction within 12 months prior to enrollment; (4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; (5) Symptomatic congestive heart failure; (6) QTc \\> 480 ms.\n* Systemic use of antibiotics ≥ 7 days within 4 weeks prior to enrollment, or unexplained fever \\> 38.5°C during screening\u002Fbefore first dose (fever due to tumor causes is allowed per investigator judgment).\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Participation in any other drug clinical study within 4 weeks or 5 half-lives prior to enrollment.\n* Known history of psychotropic drug abuse or drug addiction.\n* Presence of other severe physical or mental illnesses or laboratory abnormalities that may increase the risk of participation, interfere with study results, or render the patient unsuitable for the study in the opinion of the investigator.","80 Years",{"count":218,"type":20},32,[24],"The goal of this Phase II clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) combined with SOX chemotherapy (S-1 plus Oxaliplatin) in patients with previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer.\n\nThe main questions it aims to answer are:\n\n1、What is the objective response rate (ORR) of the combination of QL1706 and SOX chemotherapy? 2、What are the safety and tolerability of this combination therapy? Participants will：\n\n1. Receive Iparomlimab and Tuvonralimab (QL1706) via intravenous infusion every 3 weeks.\n2. Receive SOX chemotherapy (Oxaliplatin via intravenous infusion on Day 1 and S-1 orally twice daily for 14 days) every 3 weeks for up to 6 cycles.\n3. Continue maintenance therapy with QL1706 combined with S-1 after 6 cycles until disease progression or unacceptable toxicity.\n4. Undergo tumor imaging assessments (CT or MRI) every 6 weeks for the first 24 weeks, and then every 9 weeks thereafter to monitor the disease.",[222,223,40,224],"Gastric Cancer (GC)","Gastroesophageal Junction Cancer","Metastatic Gastric Cancer",[226,227,228,229,74,230,27],"Iparomlimab and Tuvonralimab","QL1706","Advanced or Metastatic Gastric Cancer","PD-1\u002FCTLA-4 Bispecific Antibody","Chemotherapy Combination","2026-01-02",{"date":233,"type":49},"2026-01-06",{"date":235,"type":49},"2025-11-04",{"date":237,"type":20},"2029-12-31",{"name":239,"class":85},"Beijing Friendship Hospital",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":86},"100612872","phase-2-optimal-methods-to-characterize-adc-resistance-in-solid-tumors-and-identify-clinically-useful-biomarkers-100612872","NCT07259226","Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","International Multicenter Multicohort Open-label Phase II Trial Aiming to Define Optimal Methods for Predicting Response\u002FResistance to Antibody-drug Conjugates in Patients With Solid Tumors Treated According to Current Standard Indications.","OASIS","Inclusion Criteria:\n\n1. Patients must have signed a written informed consent form prior to any trial specific procedures;\n2. Patients must be ≥18 years old;\n3. Histologically confirmed or radiologically documented unresectable locally advanced or metastatic cancer (Breast, Urothelial, Non small Cell Lung or Gastric) with an indication to receive an Antibody-Drug Conjugate (ADC) approved or accessible through an early access program;\n4. Patients must have at least 2 tumor lesions (primary tumor can be included): at least one measurable tumor lesion for tumor evaluation according to response evaluation criteria in solid tumors (RECIST) V1.1 and at least one tumor lesion other than bone and brain for biopsy;\n5. Patients must have a metastatic or locally advanced tumor site easily accessible to biopsy (with exception of bone and brain metastasis) and must have agreed to perform pretreatment and post-treatment biopsies; an archival pre-treatment biopsy may be used if it was collected within one month of enrolment, if no anticancer therapy was administered after the biopsy and if sufficient material is available for research;\n6. Life expectancy must be ≥12 weeks according to the discretion of the investigator;\n7. ECOG performance status ≤ 2;\n8. Patients must have adequate hematologic and organ function, compatible with ADC administration, as per drug-specific recommendations;\n9. Women of childbearing potential and male patient must agree to use adequate contraception for the duration of trial participation and up to 7 months after completing treatment for women and up to 4 months for men;\n10. Patients must be affiliated to a social security system (or equivalent);\n11. Patients must be willing and able to comply with the protocol for the duration of the trial;\n12. Patients must consent to the use of their collected tumor specimen, as well as, blood samples as detailed in the protocol for future scientific research, which includes but is not limited to DNA, RNA, and protein-based biomarker analysis.\n\nExclusion Criteria:\n\n1. Patients treated with an antibody drug conjugate in a curative setting;\n2. Patients who did not consent to sample use;\n3. Presence of another progressive pathology with short-term life-threatening prognosis;\n4. Patients undergoing concurrent treatment for a malignancy or hematologic disorder distinct from the indication for which the ADC is being administered.\n5. Patients with inadequate washout period prior to Cycle 1 Day 1, defined as:\n\n   * Whole brain radiation therapy \\\u003C14 days or stereotactic brain radiation therapy \\\u003C7 days.\n   * Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) (including another ADC) from a previous cancer treatment regimen or clinical study (other than epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)), \\\u003C14 days or 5 half-lives, whichever is longer.\n   * Immune checkpoint inhibitor therapy \\\u003C21 days.\n   * Hormonal therapy \\\u003C21 days.\n   * Major surgery (excluding placement of vascular access) \\\u003C28 days.\n   * Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation \\\u003C28 days or palliative radiation therapy \\\u003C14 days.\n6. Female participant who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 90 days after the final administration of study treatment;\n7. Person deprived of their liberty or under protective custody or guardianship.",{"count":249,"type":20},400,[24],"International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types.",[175,40,253,254],"Advanced Urothelial Cancer","Advanced Non Small Cell Lung Cancer (NSCLC)",[256,257],"ADC","resistance","2025-11-20",{"date":260,"type":49},"2025-12-02",{"date":262,"type":49},"2025-11-14",{"date":264,"type":20},"2030-11-01",{"name":266,"class":85},"UNICANCER",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":289},"100600854","phase-2-safety-and-efficacy-of-shr2554-combined-with-other-antitumor-therapies-in-gastric-or-gastro-oesophageal-junction-adenocarcinoma-100600854","NCT07102901","Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability and Efficacy of SHR2554 Tablets in Combination With Other Antitumor Therapies in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. At least 18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.\n2. Has at least 1 measurable lesion based on investigator imaging assessment (computed tomography or magnetic resonance imaging) using RECIST v1.1 at screening.\n3. Is willing to provide an adequate tumor sample.\n4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening.\n\nExclusion Criteria:\n\n1. Presence of dysphagia or other factors impairing oral administration of SHR2554.\n2. Has previously been treated with any enhancer of zeste homolog inhibitors.\n3. Uncontrolled or significant cardiovascular disease.\n4. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.\n5. Has active autoimmune diseases requiring systemic corticosteroids\u002Fimmunosuppressants.\n6. History of known hypersensitivity to SHR2554 or excipients.\n7. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection requiring treatment with intravenous (IV) antibiotics, antivirals, or antifungals.\n8. Diagnosis of other malignancies within 5 years prior to the first dose of investigational product.\n9. Has history of interstitial lung disease (ILD), non-infectious pneumonitis requiring systemic glucocorticoids, current suspected\u002Fconfirmed ILD, or clinically significant pulmonary disease history.\n10. Psychological, social, familial, or geographical factors that would prevent regular follow-up.",{"count":275,"type":20},351,[24],"This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.",[40,224,279],"Gastroesophageal Junction Adenocarcinoma","2025-09-09",{"date":282,"type":49},"2025-09-10",{"date":284,"type":49},"2025-09-05",{"date":286,"type":20},"2027-12",{"name":288,"class":56},"Jiangsu HengRui Medicine Co., Ltd.",2,{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100604090","maic-of-fruquintinib-plus-paclitaxel-versus-ramucirumab-plus-paclitaxel-in-advanced-ggej-adenocarcinoma-100604090","NCT07144995","MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G\u002FGEJ Adenocarcinoma","Adjusted Indirect Treatment Comparison of Fruquintinib-based Therapy Versus Standard Care in Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma: A MAIC Analysis.","Inclusion Criteria:\n\n* Histologically confirmed gastric\u002FGEJ adenocarcinoma\n* Advanced or metastatic disease\n* ECOG 0-1\n* Received either fruquintinib + paclitaxel or reference regimen\n* Available baseline characteristics for matching variables\n\nExclusion Criteria:\n\n* Missing key outcome data\n* Incomplete baseline characteristics for \\>2 matching variables\n* Prior fruquintinib exposure (control arm only)",{"count":298,"type":20},1143,"OBSERVATIONAL","This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia, n=440) in advanced gastric\u002FGEJ adenocarcinoma. Baseline characteristics are adjusted via entropy balancing weights. Primary endpoint is progression-free survival (PFS) analyzed by Bucher method; secondary endpoints include overall survival (OS) and objective response rate (ORR). Sensitivity analyses comprise restricted mean survival time (RMST) analysis and simulated treatment comparison (STC).",[40,279,302,303],"Fruquintinib","Ramucirumab","2025-08-20",{"date":306,"type":49},"2025-08-28",{"date":284,"type":20},{"date":309,"type":20},"2026-12-31",{"name":311,"class":85},"Sun Yat-sen University",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":21,"phases":322,"briefSummary":323,"conditions":324,"keywords":329,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":86},"100575218","phase-1-hs-10502-combination-treatment-in-patients-with-advanced-solid-tumors-100575218","NCT06769425","HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 Combination Treatment in Subjects With Advanced Solid Tumors","HS-10502","Inclusion Criteria:\n\n* Males or females aged 18 years or older (≥18 years).\n* Patients diagnosed with pathologically confirmed advanced solid tumors.\n* Subjects have at least one target lesion as assessed per the RECIST 1.1.\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.\n* Have a life expectancy of at least 12 weeks.\n* Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent until 6 months after the last dose; male subjects must agree to use barrier contraception (i.e. condoms) from signing the informed consent to 6 months after the last dose.\n* Female subjects must have a negative pregnancy test within 7 days prior to the first dose (for subjects with tumor related abnormal elevation of human chorionic gonadotropin \\[HCG\\], an ultrasound of uterus and appendages should be performed within 7 days prior to the first dose to rule out pregnancy), or demonstrate no risk for pregnancy.\n* Subject must be voluntarily enrolled in this clinical trial, be able to understand the study procedures and to sign written informed consent.\n\nExclusion Criteria:\n\n* Have received or is currently receiving the following treatment: PARPi\u002FB7-H4\u002FB7-H3-targeted therapies;\n* Have received or is currently receiving the following treatment: PARPi\u002FB7-H4\u002FB7-H3-targeted therapies;\n* Have received any of cytotoxic chemotherapy drugs, investigational drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.\n* Presence of Grade ≥ 2 toxicities as per Common Terminology Criteria for Adverse Events due to prior anti-tumor therapy.\n* Presence of pleural\u002Fabdominal effusion requiring clinical intervention.\n* Known history of other primary malignancy.\n* Evidence of brain metastasis and\u002For cancerous meningitis\n* Inadequate bone marrow reserve or hepatic\u002Frenal functions.\n* Cardiological examination abnormality.\n* Severe, uncontrolled or active cardiovascular disorders.\n* Serious or poorly controlled diabetes.\n* Serious or poorly controlled hypertension.\n* Clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose of study treatment.\n* Serious infections within 4 weeks prior to the first dose.\n* Have received systemic glucocorticoid therapy for more than 7 days within 28 days prior to the first dose study treatment, or require chronic (≥ 7 days) use of systemic glucocorticoids during the study, or have other acquired, congenital immunodeficiency disorders, or a history of organ transplantation.\n* Presence of active infectious diseases such as hepatitis B, hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus infection, etc.\n* Current hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Class B or more severe cirrhosis.\n* Any moderate or severe lung diseases that may interfere with the detection and treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.\n* History of severe neurological or psychiatric disorder.\n* Pregnant or breast-feeding women or women who intend to become pregnant during the study.\n* Attenuated live vaccination within 4 weeks prior to the first dose.\n* Subjects with autoimmune disease that is active or is likely to recur.\n* Subjects with gastrointestinal fistula, visceral fistula, gastrointestinal perforation, or abdominal abscess, or with symptoms\u002Fsigns of intestinal obstruction within 6 months prior to the first dose of study drug.\n* Subjects unlikely to comply with study procedures, restrictions and requirement as determined by the investigator.\n* Subjects with any condition that jeopardizes the safety of the patient or interferes with the assessment of the study, as judged by the investigator.",{"count":321,"type":20},157,[23],"HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.",[325,326,175,327,328,40],"Recurrent Ovarian Cancer","HER2-negative","TNBC","Advanced Prostate Cancer",[330,318,331,332,327,333,334],"Poly(ADP-ribose) polymerase-1 inhibitor","ovarian cancer","breast cancer","prostate cancer","gastric cancer","2025-06-18",{"date":337,"type":49},"2025-06-24",{"date":339,"type":49},"2025-05-07",{"date":341,"type":20},"2026-08-31",{"name":343,"class":56},"Jiangsu Hansoh Pharmaceutical Co., Ltd.",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":21,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":86},"100542686","fecal-microbiota-transplantation-fmt-in-patients-with-advanced-gastric-cancer-100542686","NCT06346093","Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer","A Prospective, Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Patients With Advanced Gastric Cancer","Inclusion Criteria:\n\nVoluntarily participate in this study and provide written informed consent. Age ≥ 18 years , male or female. Pathological confirmed locally advanced, unresectable or metastatic gastric adenocarcinoma, esophagogastric junction adenocarcinoma.\n\nAble and willing to provide tumor tissue. At least one measurable extracranial target lesion according to iRECIST. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Life expectancy ≥3 months.\n\nExclusion Criteria:\n\nPresence of absolute contra-indications to FMT administration:Toxic megacolon;Inflammatory bowel disease;Anatomic contra-indications to colonoscopy;Colectomy Patient is currently participating and receiving other study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of this study intervention.\n\nCurrently under any form of systemic antibiotics. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (\\> 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy two weeks prior to trial treatment. Patients receiving systemic steroids at physiologic doses are permitted to enroll assuming steroid dose is not above the acceptable threshold (\\> 10 mg prednisone daily or equivalent).\n\nSevere anaphylactic reaction to any food (food allergies). Had a severe hypersensitivity reaction to propofol. Has serious concomitant illnesses. The eligibility can be granted by the treating investigator on individual bases.\n\nHas HIV infection or AIDS-related illness. Has active infection of HAV, HBV or HCV. Patients with a history of Hepatitis B\u002FC infection who have received anti-viral therapy and are disease free may be considered for enrollment after discussion with Principal Investigator.\n\nPatient has received a live vaccine within 4 weeks prior to the first dose of treatment. Seasonal influenza vaccines or COVID-19 vaccines for injection are generally inactivated virus vaccines and are allowed.\n\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n\nFemales who are pregnant or breastfeeding. Active central nervous system (CNS) metastases and\u002For leptomeningeal involvement",{"count":352,"type":20},124,[168],"This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD1\u002FPDL1 therapy in the advanced gastric cancer.",[40],"2025-06-04",{"date":358,"type":49},"2025-06-10",{"date":360,"type":49},"2024-04-02",{"date":362,"type":20},"2030-06-30",{"name":364,"class":85},"Changhai Hospital",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":164,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":86},"100575065","a-multi-center-real-world-efficacy-and-safety-of-trastuzumab-deruxtecan-in-advanced-gastric-cancer-100575065","NCT06767436","A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer","A Multi-center Cohort Study to Evaluate the Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer","Inclusion Criteria:\n\n* Patients aged 19 years or older.\n* Patients with pathologically confirmed metastatic, recurrent, or unresectable gastric\u002Fgastroesophageal adenocarcinoma.\n* Patients whose tumor tissue shows HER2 immunohistochemistry (IHC) results of 3+ or 2+ with in-situ hybridization (ISH) positivity.\n* Patients who received Trastuzumab Deruxtecan as third-line or later treatment.\n\nExclusion Criteria:\n\n* Patients with HER2-negative gastric cancer.\n* Patients who did not provide consent to participate in the study.\n* Patients who received Trastuzumab Deruxtecan as first-line or second-line treatment as part of a clinical trial.",{"count":373,"type":20},300,"* Institutions will be selected\n* This study aims to collect real-world data, targeting patients who started treatment with Enhertu from September 2022, for clinical data collection\n* Among patients treated with Enhertu, those who have passed away or are no longer visiting due to hospice care will have their clinical data collected without consent until August 19, 2024\n* For patients who are scheduled to receive Enhertu treatment, are currently undergoing treatment, or have previously undergone treatment but experienced disease progression and are now receiving subsequent chemotherapy (i.e., patients with newly added data after registration)\n* Efficacy evaluation",[40],[377],"Trastuzumab-deruxtecan","2025-01-05",{"date":380,"type":49},"2025-01-09",{"date":382,"type":49},"2024-11-05",{"date":235,"type":20},{"name":385,"class":85},"Yonsei University",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":164,"maxAge":4,"enrollmentInfo":394,"targetDuration":396,"studyType":299,"phases":4,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":86},"100575066","zolbetuximab-claudin182-positive-her2-negative-advanced-gastric-cancer-100575066","NCT06767449","Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer","Multi-center Cohort Study to Evaluate the Real-world Efficacy and Safety of Zolbetuximab Plus Chemotherapy in Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer","Zolbetuximab","Inclusion Criteria:\n\n1. Patient is ≥ 19 years of age at the time of consent.\n2. The patient must have histologically confirmed locally advanced, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma\n3. Patient whose tumor expresses CLDN18.2 in ≥ 75% of tumor cells demonstrating moderate to strong membranous CLDN18 staining as determined by local or central IHC testing.\n4. The tumor sample must be HER2-negative (IHC 0, 1+, or IHC 2+\u002FISH-).\n5. The patient must have received Zolbetuximab as a first-line treatment.\n6. 1 Patient has ECOG performance status 0 or 1.\n7. Patient must meet all of the following criteria based on the locally analyzed laboratory tests collected.\n\n   * Hb ≥8 g\u002FdL (For patients who require a transfusion, it is appropriate if Hb ≥9 g\u002FdL after transfusion)\n   * ANC ≥1.0 x 10\\^9\u002FL\n   * Platelet ≥75 x 10\\^9\u002FL\n   * Total bilirubin ≤1.5 x ULN without liver metastasis, or \\\u003C3.0 x ULN if liver metastasis is present\n   * AST or ALT ≤2.5 x ULN without liver metastasis, or ≤5 x ULN if liver metastasis is present\n   * Estimated creatinine clearance ≥30 mL\u002Fmin\n\nExclusion Criteria:\n\n1. Patient has previously received treatment in a clinical trial of zolbetuximab, or a clinical trial that included zolbetuximab as 1 of the treatment options, even if the patient was not given zolbetuximab\n2. History of known or suspected hypersensitivity to Zolbetuximab, other monoclonal antibodies, or components of the used formulations.\n3. Patient has received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, patient may have received either neo-adjuvant or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as it was completed at least 6 months prior to participation.\n4. Patients who have received systemic immunosuppressive therapy, including systemic corticosteroids, within 14 days before enrollment. However, patients using physiological replacement doses of hydrocortisone or its equivalent (maximum hydrocortisone 30 mg\u002Fday or prednisone 10 mg\u002Fday), those who have received a single dose of systemic corticosteroid, or those who have received systemic corticosteroids as premedication for radiologic contrast agents are allowed.\n5. Patient has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent\u002Frecurrent vomiting\n6. Per investigator judgment, patient has significant gastric bleeding and\u002For untreated gastric ulcers that would exclude the patient from participation per investigator Judgment\n7. Patient has any other condition, which, in the opinion of the treating physician, makes the patient unsuitable to receive or tolerate zolbetuximab.",{"count":395,"type":20},80,"2 Years","* Treatment effectiveness in the real world\n* Adverse effects\n* Tissue samples collected (multiplex IHC to assess PD-L1 expression, MMR gene status, and Claudin18.2)\n* Blood samples collected (ctDNA, scRNAseq, or immune cell profiling)",[40],[392],{"date":380,"type":49},{"date":402,"type":49},"2024-12-01",{"date":404,"type":20},"2026-12-01",{"name":385,"class":85},{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":413,"enrollmentInfo":414,"targetDuration":416,"studyType":299,"phases":4,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":86},"100572032","first-line-and-neoadjuvant-immunotherapy-for-gastric-cancer-100572032","NCT06727981","First-Line and Neoadjuvant Immunotherapy for Gastric Cancer","Prospective Cohort Study on the Efficacy, Adverse Effects, and Biomarkers of First-Line\u002FNeoadjuvant Therapy With Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Age 18 years old or above\n2. Patients with advanced gastric cancer or locally advanced gastric cancer\n3. Have not received any previous anti-tumor therapy\n4. Patients expected to receive immunotherapy for first-line or neoadjuvant therapy\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n6. Adequate organ function\n\nExclusion Criteria:\n\n1. Patients with contraindications to immunotherapy\n2. Have received anti-tumor treatments such as immunotherapy and chemotherapy\n3. Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases\n4. Severe chronic or active infection requires systemic antibacterial, antifungal, or antiviral treatment, including tuberculosis infection. Have a history of active tuberculosis infection ≥ 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment\n5. History of allogeneic stem cell transplantation or organ transplantation","100 Years",{"count":415,"type":20},500,"1 Year","This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes",[40,419],"Locally Advanced Gastric Carcinoma","2024-12-10",{"date":422,"type":49},"2024-12-11",{"date":424,"type":49},"2022-01-15",{"date":426,"type":20},"2028-01-15",{"name":84,"class":85},{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":21,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":445,"leadSponsor":446,"locationsCount":4},"100570411","phase-2-a-single-arm-single-center-phase-ii-clinical-study-on-the-clinical-efficacy-and-safety-of-paclitaxel-polymeric-micelles-for-injection-combined-with-fruquintinib-capsules-in-the-second-line-treatment-of-patients-with-advanced-gastric-cancer-100570411","NCT06706895","A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer","Inclusion Criteria:\n\n\\- 1.Age ≥ 18 years ; 2. Histologically confirmed advanced gastric cancer. The first-line systemic treatment containing oxaliplatin and fluorouracil failed. According to RECIST version 1.1, there is at least one measurable lesion; 3. Eastern Cooperative Oncology Group（ECOG）score 0 or 1 ; 4.Expected survival ≥ 12 weeks ; 5.Adequate organ and bone marrow function (no hematopoietic growth factor, blood transfusion or platelet therapy was given within 1 week before the first drug treatment ):\n\n1. Blood routine: leucocyte ≥3.0×109\u002FL, absolute neutrophil count (ANC)≥1.5 ×109\u002FL, platelet count（PLT）≥ 100×109\u002FL, Hemoglobin ( Hb )≥ 9.0 g\u002FdL;\n2. Liver function : total bilirubin ≤ 1.5 ×ULN;Alanine aminotransferase(ALT)\u002Faspartate aminotransferase (AST)≤2.5×ULN without liver metastasis ;ALT\u002FAST ≤ 5 ×ULN with liver metastasis;\n3. Coagulation function : international normalized ratio (INR)≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN ;(Investigator judge that INR and APTT should be in the safe and effective treatment range for patients who are undergoing anticoagulant therapy);\n4. Renal function : serum creatinine ≤ 1.5×ULN ;\n5. Adequate cardiac function, left ventricular ejection fraction (LVEF) \\> 50 % detected by two-dimensional echocardiography.\n\n6.Understand the research and voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n* 1\\. Patients have received clinical trials of other research drugs or research instruments within 28 days before the first study of treatment ;or received anti-tumor treatment including but not limited chemotherapy, radiotherapy (excluding palliative radiotherapy completed at least 1 week before the treatment )and targeted therapy within 2 weeks before the first study of treatment; 2.The toxicity of previous anti-tumor therapy has not returned to the level of 0 or 1 (excluding alopecia ， peripheral neurotoxicity caused by chemotherapy ≤ 2) ; 3.Surgery was performed within 4 weeks before the first treatment (except biopsy) or the surgical incision was not completely healed ; 4. There were ascites requiring drainage or diuretic treatment, or pleural effusion or pericardial effusion requiring drainage or accompanied by shortness of breath within 2 weeks before the first treatment; 5.Symptomatic brain metastasis or spinal cord compression(except for previously treated patients with brain metastases, if the clinical condition was stable within 4 weeks before the first treatment and the imaging evidence did not show disease progression).\n\n  6\\. History of other primary malignant tumors in the past 5 years (except for malignant tumors that have been cured, e,g, basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in situ, breast cancer in situ).\n\n  7.History of HIV, or active bacterial or fungal infection requiring systematic treatment within 14 days before the first treatment .\n\n  8\\. HBV DNA ≥ 104copies \u002F ml or \\> 2000IU \u002F ml in the screening period ; 9.Cardiovascular diseases with significant clinical significance, including but not limited acute myocardial infarction, severe \u002F unstable angina, cerebrovascular accident or transient ischemic attack, congestive heart failure (New York Heart Association classification \\> 2) within 6 months before enrollment;other arrhythmia treated with drugs(exclude β blockers or digoxin); electrocardiogram repeated detection of QTcF interval ≥ 450 ms.; hypertension failed to be well controlled after antihypertensive drug treatment (systolic blood pressure \\> 150 mmHg, diastolic blood pressure \\> 100 mmHg ).\n\n  10.Clinically significant abnormalities in serum electrolyte levels ; 11.Women during pregnancy or lactation ; 12.Fertile but unwilling to accept effective contraception.",{"count":435,"type":20},21,[24],"This study is a single-arm, open, phase II clinical trial aimed at evaluating the anti-tumor efficacy and safety of paclitaxel polymeric micelles for injection combined with furquintinib as second-line treatment for advanced gastric cancer.",[40,439,440],"Paclitaxel Polymeric Micelles for Injection","Fruquintinib Capsules","2024-11-25",{"date":443,"type":49},"2024-11-27",{"date":402,"type":20},{"date":309,"type":20},{"name":447,"class":85},"Shanghai Zhongshan Hospital",{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":455,"targetDuration":4,"studyType":21,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":86},"100561601","phase-1-the-combination-of-adebrelimab-apatinib-and-lrinotecan-liposome-for-second-line-treatment-of-advanced-gastric-cancer-100561601","NCT06592287","The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer","Prospective, Dual Arm, Open Ib\u002FII Phase Clinical Study of the Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Age range: 18 to 75 years old, both male and female are acceptable;\n2. Patients with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma diagnosed by histology or cytology;\n3. Patients who have only received one failed systemic treatment for advanced diseases in the past; After undergoing immunotherapy, the PFS of the treatment regimen containing immune checkpoint inhibitors must be greater than 7 months;\n4. According to the evaluation criteria for solid tumor efficacy 1.1 (RECIST v1.1), there should be at least one measurable lesion that has not received local treatment such as radiotherapy (lesions located within the previously irradiated area can also be selected as target lesions if progression is confirmed);\n5. ECOG score: 0-1 point;\n6. Expected survival period ≥ 12 weeks;\n7. The main organ functions well and the laboratory test data meets the following standards: (1) Blood routine: absolute neutrophil count ≥ 1.5 × 109\u002FL (or greater than the lower limit of normal laboratory values in the research center), platelet count ≥ 100 × 109\u002FL, hemoglobin ≥ 90g\u002FL; (2) Liver function: serum total bilirubin ≤ 1.5 times the upper limit of the standard value (ULN), AST and ALT ≤ 2.5 times ULN. If the patient has liver metastasis, this standard is ≤ 5 times ULN; (3) Renal function: CrCl ≥ 60 ml\u002Fmin\u002F1.73 m2 (calculated according to the Cockcroft Gault formula);\n8. Female subjects with fertility, as well as male subjects with partners who are fertility women, are required to use a medically approved contraceptive measure (such as intrauterine devices, birth control pills, or condoms) during the study treatment period, at least 6 months after the last use of Adebrelimab, at least 6 months after the last use of Apatinib, and at least 6 months after the last use of chemotherapy;\n9. HER2 negative;\n10. Voluntarily join this study, sign informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. History of gastrointestinal perforation and\u002For fistula within 6 months prior to the first use of medication;\n2. There is uncontrollable pleural effusion, pericardial effusion, or peritoneal effusion that requires repeated drainage;\n3. Have a history of allergies to any component of Adebrelimab in the past;\n4. Have received any of the following treatments:\n\n   1. Received any other investigational drug within 4 weeks prior to the first use of the investigational drug or had a half-life of no more than 5 from the last investigational drug;\n   2. Simultaneously enrolled in another clinical study, unless it is an observational (non interventional) clinical study or an interventional clinical study follow-up;\n   3. Received anti-tumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, or tumor embolization) within 2 weeks prior to the first use of the investigational drug;\n   4. Subjects who need to receive corticosteroids (equivalent to\\>10mg prednisone per day) within 2 weeks prior to the first use of the study drug. Allow the use of hormones for routine chemotherapy pretreatment without the need for dose adjustment. Other special circumstances require communication with the researcher. In the absence of active autoimmune diseases, inhalation or local use of steroids and corticosteroids with a dosage greater than 10mg\u002Fday of prednisone efficacy dose are allowed as substitutes for adrenal cortex hormones;\n   5. Individuals who have received anti-tumor vaccines or have received live vaccines within 4 weeks prior to the first administration of the study drug;\n   6. Having undergone major surgery or suffered severe trauma within 4 weeks prior to the first use of the investigational drug;\n5. The toxicity of previous anti-tumor treatments has not recovered to ≤ CTCAE 5.0 Grade 1 (excluding hair loss) or the level specified in the inclusion\u002Fexclusion criteria;\n6. Patients with active central nervous system metastases;\n7. Active autoimmune diseases, history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to the above diseases or syndromes); Excluding childhood asthma\u002Fallergies with vitiligo or those who have already recovered, patients who do not require any intervention in adulthood; Autoimmune mediated hypothyroidism treated with stable doses of thyroid replacement hormone; Type I diabetes with a stable dose of insulin;\n8. Have a history of immune deficiency, including HIV test positive, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation and allogeneic bone marrow transplantation, or active hepatitis (hepatitis B reference: HBV DNA test value exceeds 500 IU\u002Fml or 2500 copies\u002FmL);\n9. The subject has uncontrolled cardiovascular clinical symptoms or diseases, including but not limited to: (1) NYHA class II or above heart failure; (2) Unstable angina pectoris; (3) Have experienced myocardial infarction within one year; (4) Clinically significant supraventricular or ventricular arrhythmias that have not been clinically intervened or are still poorly controlled after clinical intervention;\n10. Within 4 weeks prior to the first use of the investigational drug, there has been a severe infection (CTCAE 5.0\\>grade 2), such as severe pneumonia requiring hospitalization, bacteremia, infection complications, etc; Baseline chest imaging examination suggests the presence of active pulmonary inflammation, symptoms and signs of infection within 2 weeks prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment, except for prophylactic use of antibiotics;\n11. History of interstitial lung disease (excluding history of radiation pneumonia and non infectious pneumonia that have not been treated with steroids);\n12. Patients with active pulmonary tuberculosis infection found through medical history or CT examination, or patients with a history of active pulmonary tuberculosis infection within the past year before enrollment, or patients with a history of active pulmonary tuberculosis infection more than one year ago but without formal treatment;\n13. Diagnosed with any other malignant tumor within 5 years prior to the first use of the investigational drug, except for malignant tumors with low-risk metastasis and mortality risk (5-year survival rate\\>90%), such as basal cell or squamous cell carcinoma or cervical carcinoma in situ that have been adequately treated;\n14. Pregnant or lactating women;\n15. According to the researcher\\'s assessment, there may be other factors that could force the subject to terminate the study midway, such as having other serious illnesses (including mental illnesses) that require concurrent treatment, severe abnormal laboratory test values, family or social factors that may affect the subject\\'s safety or the collection of trial data.",{"count":456,"type":20},66,[23,24],"This study is a prospective, dual arm, open Ib\u002FII phase clinical trial, with the main objective of exploring the safety and efficacy of Adebrelimab combined with Apatinib and Lrinotecan liposome for second-line treatment of advanced gastric cancer.\n\nThe study is divided into two stages. The first stage is the safety introduction period, which includes 6 patients. Observe whether the subjects experience dose limiting toxicity (DLT) during the observation period. If no subjects experience DLT during the observation period, the study enters the next stage. The dose of Lrinotecan liposome used during the safety introduction period is 80mg\u002Fm2, and the DLTs observation period is 1 cycle. If the patient cannot tolerate it, the dose will be reduced to 60mg\u002Fm2.\n\nIn the second stage, advanced gastric cancer subjects who have progressed to first-line treatment will be included in two cohorts: those who have previously received immune checkpoint inhibitor therapy and have first-line PFS\\>7m (cohort 1) and those who have received standard systemic chemotherapy (cohort 2). 30 subjects will be included in each population, and a total of 66 subjects are planned to be enrolled.\n\nThe study includes a screening period (from the signing of the informed consent form by the subjects to the first treatment, not exceeding 28 days), a treatment period (Adebrelimab combined with Apatinib and Lrinotecan liposome), and a follow-up period (including safety and survival follow-up).",[40],[461,462,463,464,465],"Second line advanced gastric cancer","Lrinotecan liposome","Immune checkpoint inhibitors","Anti-L1 antibody","apatinib","2024-09-13",{"date":468,"type":49},"2024-09-19",{"date":470,"type":20},"2024-09-30",{"date":472,"type":20},"2026-09-30",{"name":474,"class":85},"Xianglin Yuan",{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":482,"targetDuration":4,"studyType":21,"phases":483,"briefSummary":484,"conditions":485,"keywords":486,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":4},"100553473","liposomal-irinotecan-combination-regimen-for-second-line-treatment-of-advanced-gastric-cancer-100553473","NCT06486545","Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer","Liposomal Irinotecan Combined With Albumin-bound Paclitaxel for Second-line Treatment of Advanced Gastric Cancer: a Single-arm, Single-center Clinical Study","Inclusion Criteria:\n\n* Patients fully understand the study, voluntarily participate and sign an informed consent form (ICF)\n* Age ≥18 years\n* The expected survival time is ≥3 months\n* Patients with histologically or pathologically confirmed unresectable or locally advanced gastric cancer and gastro-oesophageal junction adenocarcinoma\n* Patients who have progressed after previous first-line treatment based on fluorouracil\n* HER-2+ is known to have been previously trastuzumab or HER-2 negative\n* According to RECIST1.1 criteria, the patient had at least one measurable target lesion\n* Eastern Cooperative Oncology Group（ECOG）Physical status score: 0-2\n* Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL, platelets ≥100×10\\^9\u002FL, and hemoglobin ≥90 g\u002FL\n* Serum creatinine ≤1.5 times the upper limit of normal value; AST and ALT ≤2.5 times the upper limit of normal (≤5 times the upper limit of normal for patients with liver invasion); Total bilirubin ≤1.5 times the upper limit of normal (≤3 times the upper limit of normal for patients with liver invasion)\n* There are no contraindications for the use of liposomal irinotecan and albumin paclitaxel\n* Women of childbearing age must have had a pregnancy test (serological) negative within 7 days prior to enrollment and be willing to use an appropriate method of contraception during the trial\n* Agree to provide histological samples\n\nExclusion Criteria:\n\n* Allergic reaction to any investigational drug or its ingredients\n* Patients with relapse within 6 months after previous first-line treatment with paclitaxel\n* The investigational agent was a CYP3A4 strong inducer within 2 weeks prior to initial administration, or a CYP3A4 strong depressant or UGT1A1 strong depressant within 1 week\n* Uncontrolled systemic diseases (e.g. advanced infections, uncontrolled hypertension, diabetes, etc.)\n* Imaging confirmed intestinal obstruction\n* It has uncontrollable ascites, abdominal infection and pyloric obstruction\n* Hepatitis B, hepatitis C active infection (hepatitis B surface antigen positive and hepatitis B DNA more than 1x103 copies \u002FmL; more than 1x103 copies \u002FmL of HCV RNA)\n* Human immunodeficiency virus (HIV) infection (HIV antibody positive)\n* Previous or current co-occurrence of other malignancies (in addition to non-melanoma basal cell carcinoma of the skin that is effectively controlled, breast\u002Fcervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment within the past five years)\n* Pregnant and lactating women and patients of childbearing age who do not want to use contraception\n* The investigators determined that patients were not suitable to participate in this study",{"count":142,"type":20},[168],"Liposomal irinotecan, intravenous infusion 90min, d1:\n\nGrade 1:50mg\u002Fm2 Grade 2:60mg\u002Fm2 Grade 3:70mg\u002Fm2 Albumin-paclitaxel, 150mg\u002Fm2, intravenous infusion, d1 DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. All subjects underwent protocol-mandated examinations during treatment to observe safety and initial efficacy. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first).",[40],[487,488,489,490,491],"Gastric cancer and gastroesophageal junction adenocarcinoma","Liposomal irinotecan","Albumin-paclitaxel","Second-line treatment","Dose escalation","2024-08-23",{"date":494,"type":49},"2024-08-26",{"date":496,"type":20},"2024-08-25",{"date":498,"type":20},"2026-01-30",{"name":500,"class":85},"Hunan Cancer Hospital",{"id":502,"slug":503,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":508,"targetDuration":4,"studyType":21,"phases":509,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":519,"locationsCount":4},"100549289","early-phase-1-neoantigen-reactive-t-cells-c-for-chinese-patients-with-advanced-gastric-cancer-100549289","NCT06432075","Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer","Single Arm Clinical Prospective Study of Neoantigen Reactive T Cells (NRTs) in the Treatment of Chinese Patients With Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Voluntarily join the study and sign the informed consent;\n2. Age: 18-75 years old, male or female;\n3. Subjects with advanced gastric cancer who had received systematic standard treatment before enrollment and had no effective treatment at present. (Note: The effective treatment means refer to the latest version of the \"Gastric Cancer Diagnosis and Treatment Guide\" issued by China's \"Chinese Clinical Oncology Society\".) ;\n4. Have at least one measurable lesion according to imRECIST evaluation criteria;\n5. Expected survival ≥5 months (starting from the collection of tissue samples for sequencing);\n6. The Eastern Cancer Consortium (ECOG) score was 0 or 1 or 2;\n7. The following hematological indicators should be met: neutrophil count ≥ 1.5×109\u002FL; Hemoglobin ≥ 10.0 g\u002FdL; Platelet count ≥ 50×109\u002FL;\n8. The following biochemical indicators should be met: total bilirubin ≤2.0× upper limit of normal value (ULN); AST and ALT ≤2.0×ULN; Serum creatinine ≤1.5×ULN.\n9. Before lymphocyte clearance preadministration: 1) any chemotherapy, small molecule targeted drugs and other antitumor therapy received have passed the 3-week washout period, and the toxic side effects have returned to grade 1 or lower (excluding hair loss, vitiligo and other events as determined by the investigator to be tolerated); 2) If surgical treatment is performed within 3 weeks, toxicity has returned to grade 1 or lower; 3) The immunotoxicity of major organs has returned to grade 1 or lower after receiving any antibody drug treatment, and the washout period of PD-1 antibodies has reached 6 weeks, and CTLA-4 antibodies and other antibodies have passed the washout period of 4 weeks.\n\nExclusion Criteria:\n\n1. Subjects infected with HBV, HCV, HIV, syphilis and tuberculosis;\n2. Uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease or what the investigator considers Other diseases not included in the group;\n3. Patients with a history of bone marrow or organ transplantation; Patients with coagulation dysfunction;\n4. Patients with immune deficiency diseases or autoimmune diseases who are treated with immunosuppressive drugs;\n5. Central nervous system (CNS) metastatic and\u002For cancerous meningitis;\n6. People who may be allergic to immunotherapy;\n7. Drug abuse, clinical or psychological or social factors that affect informed consent or the conduct of the study;\n8. Pregnant and lactating women;\n9. Participating in other clinical trials;\n10. An uncertainty that the investigator believes has an impact on the subject's safety or compliance.",{"count":5,"type":20},[510],"EARLY_PHASE1","The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) in the treatment of Chinese patients with advanced gastric cancer.",[40],"2024-05-22",{"date":515,"type":49},"2024-05-29",{"date":517,"type":20},"2024-06-01",{"date":404,"type":20},{"name":520,"class":85},"First Affiliated Hospital of Wenzhou Medical University"]